Callisia N. Clarke

Abstract: Basal cell carcinoma (BCC) is the most commonly diagnosed cutaneous cancer in the United States with more than 2.5 million treated annually. Genetic studies have revealed that approximately 90% of BCCs have a mutation in the hedgehog-signaling pathway. Patients with BCC usually have an excellent prognosis with surgical modalities, however, patients with locally advanced BCC may potentially experience significant cosmetic or functional impairment, with only surgical intervention. Vismodegib is a hedgehog pathway inhibitor that has been successful in treating patients with locally advanced BCC. We report a patient with BCC with a good response to vismodegib and a novel xanthomatous change in the excision specimen.

Vismodegib

10.1097/dad.0000000000001849

Cite

Citations (1)

Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer

HPB (2020)

Ashley N. Krepline Jennifer L. Geurts Idayat Akinola Kathleen K. Christians Callisia N. Clarke

MUTYH

CHEK2

PALB2

10.1016/j.hpb.2020.03.022

Cite

Citations (2)

Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy

International Journal of Radiation Oncology*Biology*Physics (2021)

Saryleine Ortiz A. Visotcky Anjishnu Banerjee Mohammed Aldakkak Susan Tsai

FOLFIRINOX

Performance status

10.1016/j.ijrobp.2021.07.419

Cite

Citations (0)

Two-Stage Hepatectomy for Bilateral Colorectal Liver Metastases: A Multi-institutional Analysis

Annals of Surgical Oncology (2021)

Mariana Chávez Sepideh Gholami Bradford J. Kim Georgios Antonios Margonis Cecilia G. Ethun

Surgical oncology

10.1245/s10434-020-09459-6

Cite

Citations (20)

Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review

Journal of Clinical Medicine (2020)

Eliza W. Beal Lorena P. Suarez‐Kelly Charles W. Kimbrough Fabian M. Johnston Jonathan B. Greer

Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved survival for patients with colorectal peritoneal metastases (CR-PM). However, the role of neoadjuvant chemotherapy (NAC) prior to CRS-HIPEC is poorly understood. A retrospective review of adult patients with CR-PM who underwent CRS+/-HIPEC from 2000–2017 was performed. Among 298 patients who underwent CRS+/-HIPEC, 196 (65.8%) received NAC while 102 (34.2%) underwent surgery first (SF). Patients who received NAC had lower peritoneal cancer index score (12.1 + 7.9 vs. 14.3 + 8.5, p = 0.034). There was no significant difference in grade III/IV complications (22.4% vs. 16.7%, p = 0.650), readmission (32.3% vs. 23.5%, p = 0.114), or 30-day mortality (1.5% vs. 2.9%, p = 0.411) between groups. NAC patients experienced longer overall survival (OS) (median 32.7 vs. 22.0 months, p = 0.044) but similar recurrence-free survival (RFS) (median 13.8 vs. 13.0 months, p = 0.456). After controlling for confounding factors, NAC was not independently associated with improved OS (OR 0.80) or RFS (OR 1.04). Among patients who underwent CRS+/-HIPEC for CR-PM, the use of NAC was associated with improved OS that did not persist on multivariable analysis. However, NAC prior to CRS+/-HIPEC was a safe and feasible strategy for CR-PM, which may aid in the appropriate selection of patients for aggressive cytoreductive surgery.

Hyperthermic Intraperitoneal Chemotherapy

10.3390/jcm9030748

Cite

Citations (34)

Callisia N. Clarke

Papers

Citation

H-Index

i-10 index

Papers

Citation

H-Index

i-10 index